ArticleBMC research notes2009
IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay.
Article in BMC research notes, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 126 citations in OpenAlex.
- Differential Reduction of IP-10 and C-Reactive Protein via Aerobic Exercise or Mindfulness-Based Stress-Reduction Training in a Large Randomized Controlled Trial.Journal of sport & exercise psychology · 2019Trial
- Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2015Trial
- Trial
- TAK1 phosphorylation mediates macozinone (PBTZ169) induced innate immune activation against tuberculosis.mSphere · 2025Article
- Multiplexed cytokine profiling identifies diagnostic signatures for latent tuberculosis and reactivation risk stratification.PloS one · 2025Article
- Multiple cytokine analysis based on QuantiFERON-TB gold plus in different tuberculosis infection status: an exploratory study.BMC infectious diseases · 2024Article
- Specific Cytokines Analysis Incorporating Latency-Associated Antigens DifferentiatesInfection and drug resistance · 2024Article
- Performance of T-TrackDiagnostics (Basel, Switzerland) · 2023Article
- Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases.Frontiers in medicine · 2023Article
- Cytokine/chemokine profiles in people with recent infection byFrontiers in immunology · 2023Article
- A protein signature associated with active tuberculosis identified by plasma profiling and network-based analysis.iScience · 2022Article
- Biomarkers to identifyThe European respiratory journal · 2022Article
- Elevated IP-10 at the Protein and Gene Level Associates With Pulmonary TB.Frontiers in cellular and infection microbiology · 2022Article
- Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection.Scientific reports · 2021Article
- Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies.Frontiers in immunology · 2021Article
- Diagnostic benefits of adding EspC, EspF and Rv2348-B to the QuantiFERON Gold In-tube antigen combination.Scientific reports · 2020Article
- Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection.Journal of clinical microbiology · 2020Article
- Article
- Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Use of IP-10 detection in dried plasma spots for latent tuberculosis infection diagnosis in contacts via mail.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIFN-gamma responses to M. tuberculosis antigens are used as in-vitro diagnostic tests for tuberculosis infection. The tests are highly specific but sensitivity may be impaired due to immuno-suppression. The objective of this small exploratory study was to compare three novel biomarkers for in-vitro diagnosis of tuberculosis - MCP-1, MCP-3 and IL-1RA - with the current established biomarker IFN-gamma and the newly described IP-10 and MCP-2.
methodsWhole blood from 8 patents with active tuberculosis and from 7 healthy controls was stimulated with M. tuberculosis specific antigens and mitogen in the Quantiferon In Tube test tubes. Levels of biomarkers were measured using Luminex and ELISA (IFN-gamma).
resultsWe found all five new biomarkers were expressed in significantly higher concentrations compared to IFN-gamma. IP-10 and MCP-3 levels in the un-stimulated samples were higher in patients compared with controls.
conclusionAll biomarkers had diagnostic potential as they could differentiate between the patients and the controls. IP-10 and MCP-2 seemed most promising as they were expressed in high levels with antigen stimulation and were low in the un-stimulated samples. Further studies are needed to explore the potential of these highly expressed novel biomarkers individually and in combination.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.